Cash in on RFK’s FDA

The mainstream press loves giving Robert F. Kennedy Jr. a hard time.

Just don’t let it distract you from the truth.

Under RFK Jr.’s watch, Americans are about to see more medical breakthroughs than anytime in recent memory.

Expect major progress in the fights against cancer, Alzheimer’s and other deadly diseases.

And if you invest in the companies developing these revolutionary treatments now, you could lock in major gains when they become household names.

I’ll tell you more after our Top Stories and the Reader Forum.

Your Top Stories & Analysis of the Week:

• “Oil, Guns and Freedom: Alberta’s American Dream,” (Rude Awakening, Sean Ring): Mark Carney’s election victory in Canada has re-ignited Alberta’s desire to secede from the country — possibly becoming a U.S. state instead. Sean believes Donald Trump would welcome the breakaway province with open arms. He then lays out all the reasons why the move would benefit both of us — as well the obstacles preventing it from becoming a reality. Sean’s take received several Top Story nominations from readers… so it’s little surprise that it was also our most-liked e-letter of the week!

• “I Made a Huge Mistake” (The Million Mission, Davis Wilson): Davis is still trying to trade his way to $1 million. And he’d be a lot closer to his goal if he followed his own advice. A lucrative market pattern revealed itself… but Davis chose to stay on the sidelines. In this confessional essay, he walks you through exactly what he did wrong. You’ll also learn an important lesson that could prevent you from making a similar mistake.

• “The Next AI Rush Isn’t Digital” (Paradigm Mastermind Group, Chris Campbell): So far, all of the talk about artificial intelligence (AI) has focused on software applications like chatbots. But as Chris recently told Paradigm Mastermind Group members, the smart money is already starting to focus on the next stage of AI development. It’s only a matter of time before everyone else catches on to the shift — and I think you deserve to know what’s coming. So I unlocked Chris’ look ahead for you!

Remember, we publish tens to HUNDREDS of stories. The write-ups and presentations above are our TOP ones for the week — including one that had been roped off from the public. If you want to stay ahead of the pack, make sure you’re caught up now.

And if you’d like to nominate any of our stories for next week’s “Top 3,” just let me know at concierge@paradigmpressgroup.com.

The Reader Forum:

In last week’s Reader Forum, I asked if you skip our analysts’ options recommendations and just buy the underlying shares instead.

Our Concierge inbox overflowed with replies…

Mary M. tells us:

I am also a member who is into the shares choice instead of options, but I am a new member. Maybe I will consider options later as I get more comfortable. I believe the data analysis is beneficial either way you go, and I appreciate having that information to make informed decisions.

Welcome aboard, Mary — and thanks for joining the conversation!

I’m glad to hear you’re finding our research useful, even if you don’t follow our instructions to the letter.

We’re all about freedom here — especially the freedom to choose your own financial path. But please let me know if you ever decide to give options a try.

Until then, I wish you much success with your stock plays!

Next, longtime member Philippe V. says he takes Zach Scheidt’s recommendations and expands on them, adding:

I am currently long on Palantir Technologies Inc. (PLTR)... 80 shares bought at $64.57, now $127.87… Then I add to it a range of options… at $75, $80 and $100, with expiry of 1/16/26. This gives me a fairly long time to watch the market and pull the trigger… I did the same with NVIDIA Corp. (NVDA) and saw returns of greater than 1,000%! And currently with SPDR Gold Trust (GLD), which I've netted so far in two months over $10k.

Congratulations on 11 successful years with us, Phillipe… and also on the big wins that our research inspired!

We don’t currently have any services that match stock shares with options plays — but looking at your results, I wonder if we should start one.

I hope you’ll keep us updated on your progress!

Finally for today, Jay C. tells us:

Thank you so much for the forum emails! Really enjoying them! I had been meaning to ask Jim Rickards or Zach Scheidt about some foreign OTC & other securities…

I’m glad to hear that the Reader Forum is worth your time, Jay. I enjoy this weekly opportunity to address our members’ questions and concerns.

But please remember that Paradigm Press isn’t authorized to give individual investment advice. So Jim and Zach can’t share their thoughts on the list of stocks you sent — either in a personal reply or a public forum like this.

Any answer would seem like it was meant specifically for you!

You’ll also notice that I left out the specific list of stocks. That’s because over-the-counter stocks are often thinly traded. Even a little bit of buying can send their prices artificially higher.

We don’t want to even risk being accused of front-running or pumping-and-dumping stocks — letting someone take advantage of an artificial boost.

If these stocks are worth investing in, our team will find them through their proven research methods.

Then they’re free to share their analysis with whomever they want!

That wraps up this week’s Reader Forum.

Remember, your feedback is vital to our success… so please email me at concierge@paradigmpressgroup.com.

Questions? I’ll get answers! Comments? Let me hear them! Problems? I’ll try to solve them!

This is YOUR forum!

(And don’t forget, we also have a FREE library of introductory investment guides — covering everything from finding a broker to how to trade stock options — on our Wealth Desk. For customer service issues, please use our contact page.)

Now, here’s what’s happening around the water cooler this week…

The Water Cooler — Upcoming Events and More

Robert F. Kennedy Jr. was a divisive choice for Secretary of Health and Human Services.

I still see headlines every day criticizing what he says… how he runs his department… even where he swims.

That’s good news for us, though — because it means no one’s paying attention to the medical breakthroughs we’ll see during his term.

Right now, hundreds of companies are using artificial intelligence to rapidly develop and test new medicines.

They can identify false starts and zero in on promising candidates faster than ever — saving time and money in the race to save lives.

Even better, RFK Jr. is streamlining the FDA’s approval process… meaning these revolutionary treatments will be available as soon as possible.

Our Ray Blanco keeps a close eye on drug pipelines, looking for companies with an advantage in the search for next-generation cures.

He says the changes RFK Jr. is making “could dramatically cut years off development timelines and reduce research & development costs by tens of millions per drug program.”

That’s why Ray is bullish on the S&P Biotech ETF (XBI), which tracks some of the top names in tech-driven medical research.

While the ETF has struggled this year, changes at the FDA “could serve as the catalyst that finally recognizes the true value these companies represent.”

In other words, investors may finally realize what these companies are up to — and start buying in.

But Ray says the biggest opportunities are in smaller research firms that are flying under Wall Street’s radar.

In fact, Ray is tracking one small company with a breakthrough cancer treatment.

He’ll have more to say about it later this week…